6 names are moving together; 50% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| DRI | Darden Restaurants, Inc. | Consumer Cyclical | -0.5% | Group member |
| TXRH | Texas Roadhouse, Inc. | Consumer Cyclical | -1.5% | Group member |
| ALNY | Alnylam Pharmaceuticals, Inc. | Healthcare | -2.3% | Most structurally connected |
| CLMT | Calumet, Inc | Basic Materials | -0.1% | Group member |
| HALO | Halozyme Therapeutics, Inc. | Healthcare | -1.4% | Group member |
| TALK | Talkspace, Inc. | Healthcare | -0.3% | Group member |
Cohort
6 namesParticipation
50% this sessionObserved history
1 daily buildsFiling coverage
6/6 membersdemand / volume
“nded December 31, 2025, compared to the year ended December 31, 2024, primarily due to growth from AMVUTTRA revenues driven by increased patient demand, mainly in patients with ATTR-CM in the U.S., which was partially offset by a decreased number of patients on ONPATTRO, and due to growth from an increased number of patients on GIVLAARI and OXLUMO.”
ALNY 10-K
product pipeline / R&D affecting expense
“Research and development expenses increased during the year ended December 31, 2025, as compared to the year ended December 31, 2024, primarily due to the following: • increased clinical trial expenses for the ZENITH Phase 3 clinical trial of zilebesiran, the TRITON-CM Phase 3 clinical trial of nucresiran in patients with ATTR-CM and the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR-PN; • increased employee compensation and related expenses to support our research and development pipeline and development expenses; and • increased stock-based compensation expense.”
ALNY 10-K
input costs affecting expense
“Restaurant labor costs decreased as a percent of sales primarily due to a 1.2% impact from pricing and sales leverage and a 0.1% impact from productivity, partially offset by a 1.0% impact from inflation and a 0.1% impact from higher performance-based compensation expense.”
DRI 10-Q
Healthcare Biotech & Restaurants can stay leader-led if HALO and the next software names fail to join while ALNY keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.